Journal: Progress in Biomaterials

Article Title: Nanohydroxyapatite incorporated photocrosslinked gelatin methacryloyl/poly(ethylene glycol)diacrylate hydrogel for bone tissue engineering

doi: 10.1007/s40204-021-00150-x

Figure Lengend Snippet: Physical and biological properties of GMP/GMPH hydrogels. a Equilibrium swelling ratio (ESR) of GMP and GMPH hydrogels (n = 6, unpaired two-tailed t test, P = 0.0195, *P < 0.05); b Equilibrium water content (EWC) of GMP and GMPH hydrogels (n = 6, unpaired two-tailed t test, P = 0.0190, *P < 0.05); c Gelation ratio of GMP and GMPH hydrogels (n = 6, unpaired two-tailed t test, P = 0.0114, *P < 0.05); d Biodegradation assay showed an accelerated degradation rate (%) of GMP hydrogel in week 2 (n = 6, unpaired two-tailed t test, P = 0.0015, *P < 0.05). GMPH hydrogel showed a slower degradation rate than GMP hydrogel in week 2 (n = 6, unpaired two-tailed t test, P = 0.0004, *P < 0.05); e MTT assay showing the viability of MG63 cells treated with the extracts of hydrogels. All error bars represent mean ± s.e.m. GM (GelMA), GMP (GelMA/PEGDA), GMPH (GelMA/PEGDA-nanohydroxyapatite)

Article Snippet: The degradation rate (DR) of the hydrogel scaffolds was obtained from the following calculation: DR % = W 0 - W f W 0 ∗ 100 5 Cell culture MG63 osteosarcoma cell line was procured from the National Centre for Cell Science, Pune, India.

Techniques: Two Tailed Test, MTT Assay

Journal: Biochemical pharmacology

Article Title: IOX-1 suppresses metastasis of osteosarcoma by upregulating histone H3 lysine trimethylation.

doi: 10.1016/j.bcp.2023.115472

Figure Lengend Snippet: Fig. 2. Lower expression of histone H3 lysine trimethylation in human osteosarcoma tissue and cell lines correlates with increased invasive and migratory potential A, B: Migration (A) and invasion ability (B) of osteosarcoma cell lines. C: Western blot analysis of histones H3K4me3, H3K9me3 H3K27me3, H3K36me3 and H3K79me3 in the human hFOB 1.19 cell line and MG63 and HOS cell lines. D, E: Migration ability (D) and invasion ability (E) of MG63 cells and migration-prone MG63-M5 and MG63-M10 subcloned cells. F: Western blot analysis of H3K4me3, H3K9me3 and H3K27me3 expression in MG63, MG63-M5 and MG63-M10 cells. G, H: Immunohistochemistry analysis (G) and quantitative results (H) of H3K27me3 expression in human OS tissue array samples. * p < 0.05 compared with controls.

Article Snippet: Human fetal osteoblastic cell line hFOB 1.19 (CRL11372) and human OS cell lines MG63 (CRL-1543) and HOS (CRL-1543) were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA).

Techniques: Expressing, Migration, Western Blot, Immunohistochemistry

Journal: Biochemical pharmacology

Article Title: IOX-1 suppresses metastasis of osteosarcoma by upregulating histone H3 lysine trimethylation.

doi: 10.1016/j.bcp.2023.115472

Figure Lengend Snippet: Fig. 3. Increased KDM expression in human osteosarcoma tissue specimens and cell lines A: Illustration of KDMs removing methyl groups from lysine residues of a histone. B: Comparison of levels of expression for 6 KDM subtypes in 23 OS samples and 5 normal tissue control samples downloaded from the Gene Expression Omnibus (GEO) GSE14359 and GSE16088. C-F: Western blot (C, E) and quantitative analysis (D, F) of KDM subtype expression in the human hFOB 1.19 cell line and MG63 and HOS cell lines (C, D) and in the MG63 and migration-prone MG63-M5 and MG63-M10 subcloned cells (E, F). * p < 0.05 compared with controls.

Article Snippet: Human fetal osteoblastic cell line hFOB 1.19 (CRL11372) and human OS cell lines MG63 (CRL-1543) and HOS (CRL-1543) were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA).

Techniques: Expressing, Comparison, Control, Gene Expression, Western Blot, Migration

Journal: Biochemical pharmacology

Article Title: IOX-1 suppresses metastasis of osteosarcoma by upregulating histone H3 lysine trimethylation.

doi: 10.1016/j.bcp.2023.115472

Figure Lengend Snippet: Fig. 4. IOX-1 inhibits osteosarcoma cell invasion and migration, MMP mRNA and protein expression, and increases histone H3 trimethylation without affecting cell viability. A: Viability of osteosarcoma cell lines treated with increasing IOX-1 doses. B, C: Migration (A) and invasion ability (B) of MG63 and HOS cell lines subjected to different doses of IOX-1. D: Western blot analysis of H3K4me3, H3K9me3, H3K27me3 and H3K36me3 levels in MG63 and HOS cells. E: mRNA expression of MMP subtypes in hFOB 1.19 and osteosarcoma cell lines. F-I: qRT-PCR (F, H) and Western blot (G, I) analysis of MMP2, MMP3 and MMP9 mRNA and protein levels in MG63 and HOS cell lines subjected to different IOX-1 doses. * p < 0.05 compared with controls.

Article Snippet: Human fetal osteoblastic cell line hFOB 1.19 (CRL11372) and human OS cell lines MG63 (CRL-1543) and HOS (CRL-1543) were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA).

Techniques: Migration, Expressing, Western Blot, Quantitative RT-PCR

Journal: Biochemical pharmacology

Article Title: IOX-1 suppresses metastasis of osteosarcoma by upregulating histone H3 lysine trimethylation.

doi: 10.1016/j.bcp.2023.115472

Figure Lengend Snippet: Fig. 5. IOX-1 promotes epithelial markers and inhibits mesenchymal markers in human osteosarcoma cells A-B: Western blot analysis of epithelial markers E- cadherin and ZO-1 (A) and mesenchymal markers N-cadherin, vimentin, SNAIL1 and TWIST (B) protein levels in MG63 and HOS cell lines dosed with different IOX-1 concentrations. C: qRT-PCR analysis of E-cadherin mRNA levels in MG63 and HOS cells dosed with different IOX-1 concentrations. D-E: qRT-PCR analysis of mRNA expression for mesenchymal markers N-cadherin, SNAIL1 and TWIST in MG63 (D) and HOS (E) cell lines dosed with different IOX-1 concentrations. * p < 0.05 compared with controls.

Article Snippet: Human fetal osteoblastic cell line hFOB 1.19 (CRL11372) and human OS cell lines MG63 (CRL-1543) and HOS (CRL-1543) were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA).

Techniques: Western Blot, Quantitative RT-PCR, Expressing

Journal: Biochemical pharmacology

Article Title: IOX-1 suppresses metastasis of osteosarcoma by upregulating histone H3 lysine trimethylation.

doi: 10.1016/j.bcp.2023.115472

Figure Lengend Snippet: Fig. 6. IOX-1 improves the efficacy of cisplatin in cisplatin-resistant MG63-CR osteosarcoma cells A: Illustration of the process of selection of MG63 cisplatin- resistant (MG63-CR) cells. B-C: Viability of MG63 (B) and MG63-CR (C) cell lines exposed to different cisplatin concentrations. D-E: Viability of MG63 (D) and MG63- CR (E) cell lines administered cisplatin and IOX-1, alone or in combination. F: Western blot analysis of ABCB1, ABCG2 and ABCC1 protein levels in MG63 and MG-CR cell lines and in MG63-CR cell lines subjected to different IOX-1 concentrations. G: qRT-PCR analysis of ABCB1, ABCG2 and ABCC1 mRNA expression in MG63 and MG63-CR cell lines. H: Western blot analysis of H3K4me3, H3K9me3 H3K27me3 and H3K36me3 expression in MG63, MG63-CR and MG63-CR cell lines treated with different IOX-1 concentrations. * p < 0.05 compared with controls.

Article Snippet: Human fetal osteoblastic cell line hFOB 1.19 (CRL11372) and human OS cell lines MG63 (CRL-1543) and HOS (CRL-1543) were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA).

Techniques: Selection, Western Blot, Quantitative RT-PCR, Expressing

Journal: Biochemical pharmacology

Article Title: IOX-1 suppresses metastasis of osteosarcoma by upregulating histone H3 lysine trimethylation.

doi: 10.1016/j.bcp.2023.115472

Figure Lengend Snippet: Fig. 7. IOX-1 reduces stem cell populations and cancer stem cell markers in human osteosarcoma cell lines A-D: Sphere formation of OS stem cells. (A, B) Images and quantification of spheres in MG63 cells, MG63-M5 and MG63-M10 subcloned cells; (C, D) Images and quantification of spheres in MG63 cells and MG63- CR cells. E-F: Western blot analysis of stem cell marker expression (NANOG, SOX2 and OCT4) in MG63, MG63-M5 and MG63-M10 cells (E) and in MG63 and MG63- CR cells (F). G-J: Sphere formation of OS stem cells. (G, I) Images of spheres and (H, J) quantification of spheres in MG63 and HOS cells dosed with different IOX-1 concentrations. K-L: qRT-PCR analysis of mRNA levels of stem cell markers in MG63 (K) and HOS (L) cells with increasing IOX-1 exposure. M−N: Western blot analysis of stem cell marker expression (NANOG, SOX2 and OCT4) in MG63 (M) and HOS (N) cells with increasing IOX-1 doses. * p < 0.05 compared with controls.

Article Snippet: Human fetal osteoblastic cell line hFOB 1.19 (CRL11372) and human OS cell lines MG63 (CRL-1543) and HOS (CRL-1543) were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA).

Techniques: Western Blot, Marker, Expressing, Quantitative RT-PCR

Journal: Biochemical pharmacology

Article Title: IOX-1 suppresses metastasis of osteosarcoma by upregulating histone H3 lysine trimethylation.

doi: 10.1016/j.bcp.2023.115472

Figure Lengend Snippet: Fig. 8. Knockdown of SOX2 reduces MG63-M10 cell migration and levels of mesenchymal marker expression and en hances cisplatin efficacy by reducing levels of ABC proteins in MG63-CR cells A: Cell migration analysis showing that SOX shRNA1 and shRNA2 decreases migration of MG63-M10 cells. B: Western blot analysis indicating that SOX2 shRNA1 and shRNA2 decrease levels of SOX2, MMP9 and mesen chymal marker protein expression in MG63- M10 cells. C: Analysis of cell viability shows that SOX2 shRNAs sensitize MG63-CR cells to cisplatin. D: Western blot analysis indicates that SOX2 shRNA1 and shRNA2 decrease SOX2 and ABC protein subtypes in MG63-CR cells. * p < 0.05 compared with controls.

Article Snippet: Human fetal osteoblastic cell line hFOB 1.19 (CRL11372) and human OS cell lines MG63 (CRL-1543) and HOS (CRL-1543) were purchased from the American Type Culture Collection (ATCC, Manassas, VA, USA).

Techniques: Knockdown, Migration, Marker, Expressing, Western Blot

Journal: Scientific Reports

Article Title: Telomerase reverse transcriptase promotes chemoresistance by suppressing cisplatin-dependent apoptosis in osteosarcoma cells

doi: 10.1038/s41598-017-07204-w

Figure Lengend Snippet: TERT expression is altered and shuttles from the nucleus to mitochondria in cisplatin-treated osteosarcoma cells. ( A ) The relative mRNA expression of TERT were determined by qRT-PCR in cisplatin treated or untreated osteosarcoma cells including MG63, U2OS and 143B. ( B ) The relative protein expression of TERT were analyzed by Western-blot in cisplatin treated or untreated osteosarcoma cell lines. ( C ) Confocal images from MG63, U2OS and 143B cells untreated (control, upper panel) or treated with 5 μmol/L cisplatin for 24 h (lower panel). Green anti-TERT immune-fluorescence, red mitotracker and blue nuclear DNA (DAPI). Marked colocalization between green anti-TERT and red mitotracker is displayed by green-red mixing. ( D ) Mitochondrial fractions of cisplatin treated or untreated cells were subjected to Western blot analysis of TERT and VDAC. All experiments were carried out at least triplicates and the data were presented as the mean ± S.D. Student t test was performed to evaluate the difference *P < 0.05.

Article Snippet: The human osteosarcoma cell lines MG63, U2OS and 143B were obtained from China Centre for Type Culture Collection (CCTCC).

Techniques: Expressing, Quantitative RT-PCR, Western Blot, Control, Fluorescence

Journal: Scientific Reports

Article Title: Telomerase reverse transcriptase promotes chemoresistance by suppressing cisplatin-dependent apoptosis in osteosarcoma cells

doi: 10.1038/s41598-017-07204-w

Figure Lengend Snippet: TERT reduces apoptosis induced by cisplatin in osteosarcoma cells independently of telomerase reverse transcriptase activity. ( A ) The relative TERT expression in mock transfected cells (control), TERT-overexpressing cells (TERT-WT, TERT-CI) and TERT-siRNA cells were assessed by Western blot analysis. ( B ) MG63 transfected cells were treated with 5 μmol/L cisplatin for 24 hours after which the apoptosis in cells was detected by flow cytometry. ( C ) U2OS transfected cells were treated wit with 5μmol/L cisplatin for 24 hours after which the apoptosis in cells was assessed by Immuno-fluorescence. Karyopyknosis is taken as apoptosis. ( D ) Quantification of apoptotic rate in cisplatin-treated osteosarcoma transfected cell lines detected by FACS. All experiments were carried out at least triplicates and the data were presented as the mean ± S.D. Student t test was performed to evaluate the difference *P < 0.05.

Article Snippet: The human osteosarcoma cell lines MG63, U2OS and 143B were obtained from China Centre for Type Culture Collection (CCTCC).

Techniques: Reverse Transcription, Activity Assay, Expressing, Transfection, Control, Western Blot, Flow Cytometry, Fluorescence

Journal: Oncotarget

Article Title: Crosstalk between the IGF-1R/AKT/mTORC1 pathway and the tumor suppressors p53 and p27 determines cisplatin sensitivity and limits the effectiveness of an IGF-1R pathway inhibitor

doi: 10.18632/oncotarget.8484

Figure Lengend Snippet: MHM, U2OS and S4 cells expressing control shRNA (shc) or p53 shRNA (shp53) were treated with 10 μM CP and MG63 (p53-null) cells were treated with 5 μM CP alone or in combination with OSI-906 (5 μM) for 48 hours. The cells were then rinsed and re-fed with drug free media and cells were collected after 5 days and analyzed by flow cytometry for cell cycle. Representative cell cycle profile histograms are shown and percentage of cells with Sub-G1 DNA content are plotted. Shown are the mean results of three experiments, bars , Standard error (SE). *significance value ( P < 0.05).

Article Snippet: SJSA1, U2OS, MG63 osteosarcoma cells were obtained from ATCC.

Techniques: Expressing, Control, shRNA, Flow Cytometry

Journal: Oncotarget

Article Title: Crosstalk between the IGF-1R/AKT/mTORC1 pathway and the tumor suppressors p53 and p27 determines cisplatin sensitivity and limits the effectiveness of an IGF-1R pathway inhibitor

doi: 10.18632/oncotarget.8484

Figure Lengend Snippet: ( A ) MHM, U2OS and S4 cells expressing control shRNA (shc) or p53 shRNA (shp53) and MG63 (p53-null) cells were treated with 2.5 μM CP alone or in combination with OSI-906 (5 μM) for 48 hours. The cells were then rinsed and re-fed with drug free medium and the percentage of senescent cells (flat and SA-β-gal positive) determined after 5 days. The SA-β-gal positive cells were counted and normalized with plating efficiency. Shown are the mean results of three experiments, bars, Standard error (SE). *significance value ( P < 0.05). ( B ) MHM, U2OS and S4 cells expressing control shRNA (shc) or p53 shRNA (shp53) and MG63 cells were treated with 2.5 μM CP alone or in combination with OSI-906 (5 μM) for 48 hours. The cells were then rinsed and re-fed with drug free media and colonies stained with crystal violet 2–3 weeks later. The colonies were counted and normalized with plating efficiency of untreated cells. Shown are the mean results of three experiments, bars, Standard error (SE). *significance value ( P < 0.05).

Article Snippet: SJSA1, U2OS, MG63 osteosarcoma cells were obtained from ATCC.

Techniques: Expressing, Control, shRNA, Staining

Journal: Oncotarget

Article Title: Crosstalk between the IGF-1R/AKT/mTORC1 pathway and the tumor suppressors p53 and p27 determines cisplatin sensitivity and limits the effectiveness of an IGF-1R pathway inhibitor

doi: 10.18632/oncotarget.8484

Figure Lengend Snippet: MHM, U2OS and S4 cells expressing control shRNA (shc) or p53 shRNA (shp53) and MG63 cells were untreated or treated with 10 μM CP alone or in combination with OSI-906 (5 μM) for 24 hours. Lysates were immunoblotted with antibodies against p27 and Actin.

Article Snippet: SJSA1, U2OS, MG63 osteosarcoma cells were obtained from ATCC.

Techniques: Expressing, Control, shRNA

Journal: Oncotarget

Article Title: Crosstalk between the IGF-1R/AKT/mTORC1 pathway and the tumor suppressors p53 and p27 determines cisplatin sensitivity and limits the effectiveness of an IGF-1R pathway inhibitor

doi: 10.18632/oncotarget.8484

Figure Lengend Snippet: MHM, U2OS and S4 cells expressing control shRNA (shc) or p53 shRNA (shp53) and MG63 (p53-null) cells were transfected with control siRNA (sic) and p27 siRNA (sip27) and treated with 10 μM CP alone or in combination with OSI-906 (5 μM) for 48 hours. The cells were then rinsed and re-fed with drug free medium and cells were collected 5 days and analyzed by flow cytometry for cell cycle. Representative cell cycle profile histograms are shown and percentage of cells with Sub-G1 DNA content are plotted. Shown are the mean results of three experiments, bars , Standard error (SE). *significance value ( P < 0.05).

Article Snippet: SJSA1, U2OS, MG63 osteosarcoma cells were obtained from ATCC.

Techniques: Expressing, Control, shRNA, Transfection, Flow Cytometry

Journal: Oncotarget

Article Title: Crosstalk between the IGF-1R/AKT/mTORC1 pathway and the tumor suppressors p53 and p27 determines cisplatin sensitivity and limits the effectiveness of an IGF-1R pathway inhibitor

doi: 10.18632/oncotarget.8484

Figure Lengend Snippet: MHM, U2OS, and S4 cells expressing control shRNA (shc) or p53 shRNA (shp53) and MG63 (p53-null) cells were transfected with control siRNA (sic) and p27 siRNA (sip27) and treated with 2.5 μM CP alone or in combination with OSI-906 (5 μM) for 48 hours. Representative cell cycle profile histograms at the time of harvest are shown ( Left ) and the percentage of G1-phase cells plotted +/− SE from 3 experiments ( Right ).

Article Snippet: SJSA1, U2OS, MG63 osteosarcoma cells were obtained from ATCC.

Techniques: Expressing, Control, shRNA, Transfection

Journal: Oncotarget

Article Title: Crosstalk between the IGF-1R/AKT/mTORC1 pathway and the tumor suppressors p53 and p27 determines cisplatin sensitivity and limits the effectiveness of an IGF-1R pathway inhibitor

doi: 10.18632/oncotarget.8484

Figure Lengend Snippet: MHM, U2OS, and S4 cells expressing control shRNA (shc) or p53 shRNA (shp53) and MG63 (p53-null) cells were transfected with control siRNA (sic) and p27 siRNA (sip27) and treated with 2.5 μM CP alone or in combination with OSI-906 (5 μM) for 48 hours. The cells were then rinsed and re-fed with drug free medium and colonies stained with crystal violet 2–3 weeks later. The colonies were counted and normalized with plating efficiency of untreated cells. Plotted are the mean results of three experiments, bars, Standard error (SE). *significance value ( P < 0.05).

Article Snippet: SJSA1, U2OS, MG63 osteosarcoma cells were obtained from ATCC.

Techniques: Expressing, Control, shRNA, Transfection, Staining

Journal: International journal of molecular sciences

Article Title: Sorafenib and Doxorubicin Show Synergistic Effects in Human and Canine Osteosarcoma Cell Lines.

doi: 10.3390/ijms23169345

Figure Lengend Snippet: Figure 1. Cell viability was measured by CellTiter-Glo assay on all seven OSA cell lines, including four canine OSA (D17, Abrams, Gracie, and BZ) and three human OSA (SAOS2, U2OS, and MG63) cell lines. All cell lines were treated with drugs for 72 h. (A) Ten TKIs demonstrate different levels of inhibition on OSA cell viability. (B) OSA cell lines were treated with sorafenib for 72 h. (C) OSA cell lines were treated with doxorubicin.

Article Snippet: Canine OSA cell line D17 and human OSA cell line (SAOS2, U2OS, and MG63) were purchased from ATCC.

Techniques: Glo Assay, Inhibition

Journal: International journal of molecular sciences

Article Title: Sorafenib and Doxorubicin Show Synergistic Effects in Human and Canine Osteosarcoma Cell Lines.

doi: 10.3390/ijms23169345

Figure Lengend Snippet: Figure 2. Photomicrographs taken with Nikon camera at 40× magnification, comparing wound healing in three OSA cell lines with and without sorafenib for up to 48 h. (D17: 3 µM, Abrams: 4 µM, SAOS2: 3 µM). **: p < 0.01, *: p < 0.05, and ns (not significant) for sorafenib treatment compared to control as determined by two-way ANOVA with Tukey’s multiple comparison test.

Article Snippet: Canine OSA cell line D17 and human OSA cell line (SAOS2, U2OS, and MG63) were purchased from ATCC.

Techniques: Control, Comparison

Journal: bioRxiv

Article Title: Acoustofluidic patterning for improved microtissue histology

doi: 10.1101/2025.02.09.637288

Figure Lengend Snippet: a) Schematic of the histology process for paraffin infiltrated samples. The process consisted of sample dehydration by incubating in a series of ethanol and xylene solutions followed by paraffin embedding and sectioning with a microtome. Finally, the sections were stained and imaged. b) Microtissue histology (H&E staining) of acoustofluidically patterned and multiplexed, HepG2 microtissues within paraffin-embedded sections. The images correspond to serial sections spaced 45 μm apart. c) Zoomed-in-view of the section in b, to show the morphology of HepG2 microtissues. d) Paraffin sections containing three types of osteosarcoma cell lines (HOS, MG63, and Saos-2) stained with H&E. Patterned samples with each of these microtissues were multiplexed within one HistoGel slab (left) Zoomed in view of each spheroid type (center and right).

Article Snippet: Human osteosarcoma HOS (CRL1543, ATCC, USA), MG63 (Mayo Clinic, USA) and Saos-2 cells (ACC 243, Leibniz Institute DSMZ, Germany) were cultured DMEM-F12 Ham mixture (D8437, Sigma-Aldrich, USA), supplemented with 10% FBS (F4135, Sigma-Aldrich, USA), 2mM L-Glutamine (G7513, Sigma-Aldrich, USA), and 1% P/S (P4333, Sigma-Aldrich, USA).

Techniques: Staining